Scarica l'app Stockscreener
10.85
3.33%
0.35
Dopo l'orario di chiusura:
10.36
-0.49
-4.52%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché NMRA Giù?
Forum
Previsione
Precedente Chiudi:
$10.50
Aprire:
$10.17
Volume 24 ore:
1.79M
Relative Volume:
1.57
Capitalizzazione di mercato:
$1.75B
Reddito:
-
Utile/perdita netta:
$-274.18M
Rapporto P/E:
-6.3147
EPS:
-1.7182
Flusso di cassa netto:
$-198.33M
1 W Prestazione:
+5.14%
1M Prestazione:
+10.83%
6M Prestazione:
+22.60%
1 anno Prestazione:
-25.07%
Intervallo 1D:
$10.07
$11.10
Intervallo di 1 settimana:
$9.89
$11.16
Portata 52W:
$8.33
$21.00
Neumora Therapeutics Inc Stock (NMRA) Company Profile
Nome
Neumora Therapeutics Inc
Settore
Industria
Telefono
(857) 760-0900
Indirizzo
490 ARSENAL WAY, SUITE 200, WATERTOWN
Confronta NMRA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NMRA
Neumora Therapeutics Inc
|
10.85 | 1.75B | 0 | -274.18M | -198.33M | -2.5346 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Neumora Therapeutics Inc Stock (NMRA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-05 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-10-01 | Iniziato | H.C. Wainwright | Buy |
| 2024-07-22 | Iniziato | Needham | Buy |
| 2024-07-08 | Iniziato | Mizuho | Outperform |
| 2023-12-12 | Iniziato | Deutsche Bank | Hold |
| 2023-10-10 | Iniziato | BofA Securities | Buy |
| 2023-10-10 | Iniziato | Guggenheim | Buy |
| 2023-10-10 | Iniziato | JP Morgan | Overweight |
| 2023-10-10 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-10-10 | Iniziato | Stifel | Buy |
| 2023-10-10 | Iniziato | William Blair | Outperform |
Mostra tutto
Neumora Therapeutics Inc Borsa (NMRA) Ultime notizie
Neumora Therapeutics Inc put volume heavy and directionally bearish - TipRanks
Commit To Buy Neumora Therapeutics At $5, Earn 105.2% Annualized Using Options - Nasdaq
(NMRA) Trading Report - Stock Traders Daily
What is HC Wainwright’s Estimate for NMRA Q1 Earnings? - Defense World
Q1 Earnings Forecast for NMRA Issued By HC Wainwright - MarketBeat
HC Wainwright Reaffirms “Buy” Rating for Neumora Therapeutics (NASDAQ:NMRA) - Defense World
Neumora Therapeutics (NASDAQ:NMRA) Given Buy Rating at HC Wainwright - Defense World
Neumora Therapeutics (NASDAQ:NMRA) Earns Buy Rating from HC Wainwright - MarketBeat
Neumora shares retain Buy rating ahead of clinical trial results By Investing.com - Investing.com Canada
Neumora Therapeutics' SWOT analysis: stock's potential in depression treatment market - Investing.com
Stock Traders Purchase High Volume of Neumora Therapeutics Call Options (NASDAQ:NMRA) - Defense World
Point72 Asset Management L.P. Takes Position in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - MarketBeat
The Manufacturers Life Insurance Company Trims Holdings in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - Defense World
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Holdings Raised by Charles Schwab Investment Management Inc. - MarketBeat
(NMRA) Proactive Strategies - Stock Traders Daily
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Shares Acquired by Wexford Capital LP - MarketBeat
Intech Investment Management LLC Makes New $175,000 Investment in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - Defense World
RBC maintains $29 target on Neumora amid JNJ trial update By Investing.com - Investing.com UK
Fmr LLC Trims Stake in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - MarketBeat
Cerity Partners LLC Purchases New Stake in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - MarketBeat
Head-To-Head Analysis: Neumora Therapeutics (NMRA) vs. Its Competitors - Defense World
Neumora Therapeutics' SWOT analysis: stock poised for growth amid MDD trial - Investing.com Canada
Neumora Therapeutics’ (NMRA) Outperform Rating Reiterated at Royal Bank of Canada - Defense World
Neumora Therapeutics' (NMRA) Outperform Rating Reiterated at Royal Bank of Canada - MarketBeat
Contrasting Neumora Therapeutics (NMRA) and Its Competitors - Defense World
Head-To-Head Survey: Neumora Therapeutics (NMRA) vs. Its Rivals - Defense World
Neumora Therapeutics, Inc. (NMRA): This Small-Cap Stock Is Ready To Explode - MSN
This biotech’s stock could double if its treatment for major depressive disorder succeeds, says Mizuho - MSN
10 Best Small-Cap Stocks Ready To Explode - Insider Monkey
Financial Comparison: Neumora Therapeutics (NMRA) and Its Rivals - Defense World
HC Wainwright Issues Pessimistic Forecast for NMRA Earnings - Defense World
Analysts Set Neumora Therapeutics, Inc. (NASDAQ:NMRA) Target Price at $21.67 - Defense World
Equities Analysts Set Expectations for NMRA FY2024 Earnings - Defense World
FY2024 Earnings Forecast for NMRA Issued By William Blair - MarketBeat
HC Wainwright Analysts Lower Earnings Estimates for NMRA - MarketBeat
Noteworthy Friday Option Activity: NMRA, WMT, CMRE - Nasdaq
This biotech’s stock may double on treatment for depression, says Mizuho - MarketWatch
SoftBank Group Corp.'s Strategic Reduction in Neumora Therapeuti - GuruFocus.com
Neumora Therapeutics (NASDAQ:NMRA) Announces Earnings Results, Misses Estimates By $0.06 EPS - MarketBeat
Needham & Company LLC Reiterates Buy Rating for Neumora Therapeutics (NASDAQ:NMRA) - MarketBeat
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives $21.67 Average PT from Analysts - MarketBeat
Neumora Therapeutics Reports Q3 2024 Financial Results - TipRanks
Neumora Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times
Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire Inc.
Where Do Analysts Think The Neumora Therapeutics Inc (NASDAQ: NMRA) Is Going - Stocks Register
Neumora Therapeutics (NMRA) to Release Quarterly Earnings on Tuesday - Defense World
Objective long/short (NMRA) Report - Stock Traders Daily
Neumora Therapeutics downgraded to Neutral from Overweight at JPMorgan - MSN
What You Didn’t Know About Neumora Therapeutics Inc (NASDAQ: NMRA) This Week - Stocks Register
Neumora Therapeutics Inc Azioni (NMRA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Neumora Therapeutics Inc Azioni (NMRA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Fust Matthew K | Director |
Oct 17 '24 |
Option Exercise |
6.81 |
7,739 |
52,730 |
27,839 |
| Fust Matthew K | Director |
Oct 18 '24 |
Sale |
17.03 |
14,049 |
239,319 |
20,100 |
| Fust Matthew K | Director |
Oct 17 '24 |
Sale |
17.01 |
7,739 |
131,643 |
20,100 |
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):